Gene polymorphisms and motor levodopa-induced complications in Parkinson's disease. 2020

Małgorzata Michałowska, and Małgorzata Chalimoniuk, and Ewa Jówko, and Iwona Przybylska, and Józef Langfort, and Beata Toczylowska, and Anna Krygowska-Wajs, and Urszula Fiszer
Department of Neurology and Epileptology, Centre of Postgraduate Medical Education, Orłowski Hospital, Warsaw, Poland.

The aim of the study was to evaluate the association of individual and combined single-nucleotide polymorphisms in brain-derived neurotrophic factor (BDNF), dopamine transporter (DAT), and catechol-O-methyltransferase (COMT) genes with the occurrence of motor levodopa-induced complications (MLIC) in Parkinson's disease (PD). We studied 76 patients with PD (MLIC occurred in 56.6%) and 60 controls. Allelic discrimination of rs6265 BDNF (Val66Met), rs397595 DAT (SLC6A3), and rs4680 COMT (Val158Met) genes were genotyped. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated using multinominal logistic regression. Orthogonal partial least squares (OPLS) analysis and OPLS discriminant analysis (OPLS-DA) were used to analyze qualitative genetic data. The risk of PD in subjects with the AG BDNF genotype was increased sixfold (OR = 6.12, 95% CI = 2.88-13.02, p < .0001), and AG BDNF and AG DAT genotypes were correlated with PD in OPLS-DA (VIP > 1). There were no differences in distributions of BDNF, DAT and COMT genotypes between PD groups with and without MLIC, while OPLS model showed that genotype combination of AG BDNF, AG DAT, and GG COMT was correlated with MLIC and genotypes combination of GG BDNF, AA DAT, and AA COMT with lack of MLIC in PD patients (VIP > 1). Our results confirmed the association of rs6265 BDNF (Val66Met) with the risk of PD and suggest a synergic effect of rs6265 BDNF (Val66Met), rs397595 DAT (SLC6A3), and rs4680 COMT (Val158Met) polymorphisms on the occurrence of MLIC.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010597 Pharmacogenetics A branch of genetics which deals with the genetic variability in individual responses to drugs and drug metabolism (BIOTRANSFORMATION). Pharmacogenomics
D002394 Catechol O-Methyltransferase Enzyme that catalyzes the movement of a methyl group from S-adenosylmethionone to a catechol or a catecholamine. Catechol Methyltransferase,Catechol-O-Methyltransferase,Catechol O Methyltransferase,Methyltransferase, Catechol,O-Methyltransferase, Catechol
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D005260 Female Females
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Małgorzata Michałowska, and Małgorzata Chalimoniuk, and Ewa Jówko, and Iwona Przybylska, and Józef Langfort, and Beata Toczylowska, and Anna Krygowska-Wajs, and Urszula Fiszer
June 2016, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego,
Małgorzata Michałowska, and Małgorzata Chalimoniuk, and Ewa Jówko, and Iwona Przybylska, and Józef Langfort, and Beata Toczylowska, and Anna Krygowska-Wajs, and Urszula Fiszer
January 2000, The Cochrane database of systematic reviews,
Małgorzata Michałowska, and Małgorzata Chalimoniuk, and Ewa Jówko, and Iwona Przybylska, and Józef Langfort, and Beata Toczylowska, and Anna Krygowska-Wajs, and Urszula Fiszer
May 2006, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
Małgorzata Michałowska, and Małgorzata Chalimoniuk, and Ewa Jówko, and Iwona Przybylska, and Józef Langfort, and Beata Toczylowska, and Anna Krygowska-Wajs, and Urszula Fiszer
October 2000, Trends in neurosciences,
Małgorzata Michałowska, and Małgorzata Chalimoniuk, and Ewa Jówko, and Iwona Przybylska, and Józef Langfort, and Beata Toczylowska, and Anna Krygowska-Wajs, and Urszula Fiszer
January 2000, The Cochrane database of systematic reviews,
Małgorzata Michałowska, and Małgorzata Chalimoniuk, and Ewa Jówko, and Iwona Przybylska, and Józef Langfort, and Beata Toczylowska, and Anna Krygowska-Wajs, and Urszula Fiszer
July 2022, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,
Małgorzata Michałowska, and Małgorzata Chalimoniuk, and Ewa Jówko, and Iwona Przybylska, and Józef Langfort, and Beata Toczylowska, and Anna Krygowska-Wajs, and Urszula Fiszer
January 2019, Neuroscience letters,
Małgorzata Michałowska, and Małgorzata Chalimoniuk, and Ewa Jówko, and Iwona Przybylska, and Józef Langfort, and Beata Toczylowska, and Anna Krygowska-Wajs, and Urszula Fiszer
July 2011, Expert opinion on drug metabolism & toxicology,
Małgorzata Michałowska, and Małgorzata Chalimoniuk, and Ewa Jówko, and Iwona Przybylska, and Józef Langfort, and Beata Toczylowska, and Anna Krygowska-Wajs, and Urszula Fiszer
December 1997, Clinical neuropharmacology,
Małgorzata Michałowska, and Małgorzata Chalimoniuk, and Ewa Jówko, and Iwona Przybylska, and Józef Langfort, and Beata Toczylowska, and Anna Krygowska-Wajs, and Urszula Fiszer
January 1999, Revista de neurologia,
Copied contents to your clipboard!